Ecnoglutide

Verdiva Bio is running NCT07281937, a Phase 2 trial of weekly oral ecnoglutide (VRB-101) in 206 patients with obesity or overweight plus weight-related comorbidities. The same molecule has cleared Phase 3 in China under Hangzhou Sciwind Biosciences (as XW003) for both type 2 diabetes and obesity, with the obesity trial reporting roughly 10-12% placebo-adjusted weight loss at week 48 [1] and the T2D head-to-head beating dulaglutide [3]. Verdiva is developing the oral once-weekly formulation under what appears to be an ex-Greater China license from Sciwind, backed by a sizeable 2025 Series A from cardiometabolic-focused crossover investors [6]. The differentiator pitch is the oral once-weekly format - most GLP-1 receptor agonists are weekly injections, and the only marketed oral GLP-1 (Rybelsus/semaglutide) is daily with strict fasting rules and roughly half the weight loss of injectable semaglutide. The competitive question is whether VRB-101 can reach Phase 3 before Lilly's small-molecule oral orforglipron does, since orforglipron sidesteps the peptide oral bioavailability problem entirely. The Phase 2 readout, expected Q3-Q4 2026 based on ACTIVE_NOT_RECRUITING status, is the next signal worth watching.

Ecnoglutide is a novel compound from the US/EU regulatory perspective. No FDA or EMA approval, no breakthrough therapy, fast track, or orphan designation. It is, however, well-characterized at the molecule level: Hangzhou Sciwind Biosciences has completed multiple Phase 3 trials in China - EECOH-1 in T2D monotherapy versus placebo [2], EECOH-2 versus dulaglutide in T2D [3], and a Phase 3 obesity trial [1] - with data published in Nature Communications and Lancet Diabetes & Endocrinology between 2025 and 2026. A 2026 meta-analysis summarized the T2D efficacy and safety profile [5]. Verdiva Bio Development is running the weekly oral formulation in NCT07281937. Verdiva itself launched in January 2025 with a ~$410M Series A from Forbion, General Atlantic, Lilly Ventures, RA Capital, OrbiMed, and others, built around an in-licensed cardiometabolic portfolio from Sciwind that includes ecnoglutide for territories outside Greater China [6]. The cash position is more than enough to reach Phase 2 readout and fund early Phase 3 planning, which removes near-term runway risk from the thesis. Trial status: ACTIVE_NOT_RECRUITING with n=206 enrolled. No public guidance on readout date, but ACTIVE_NOT_RECRUITING typically implies primary endpoint readout within 6-12 months, putting the expected window at Q3-Q4 2026. Sciwind's own Phase 3 program for the injectable continues in adjacent indications, including obstructive sleep apnea (NCT07387094, NCT07434050).

GLP-1 (glucagon-like peptide-1) is a hormone the gut releases after eating. It tells the pancreas to make insulin, tells the brain you're full, and slows how fast the stomach empties. Drugs that activate the GLP-1 receptor - semaglutide (Wegovy/Ozempic), tirzepatide (Zepbound/Mounjaro, which adds GIP), liraglutide (Saxenda), dulaglutide, exenatide - produce 15-22% body weight loss in obesity trials and have built a category worth over $50 billion in annual sales. Ecnoglutide is described in the Phase 3 papers as a cAMP-biased GLP-1 agonist [2][3], meaning it preferentially activates the cAMP signaling arm of the receptor while reducing β-arrestin recruitment (β-arrestin is a protein that dampens the receptor's signal after activation, so reducing its recruitment shifts which downstream pathways dominate). The theoretical pitch: better metabolic effect (insulin secretion, weight loss) with less GI signaling (nausea, vomiting). Whether that pans out in head-to-head data is unsettled - published GI adverse-event rates from the Sciwind Phase 3 trials are in the same broad range reported for semaglutide and dulaglutide (nausea, vomiting, and diarrhea as the dominant AEs driving discontinuations [1][2][3]), so the bias-signaling story has not produced a dramatically cleaner tolerability profile in the data so far. Mechanism risk is essentially zero. GLP-1R is the most validated target in metabolic disease with five-plus approved agonists. The real question is differentiation against an entrenched standard of care.

NCT07281937 is a placebo-controlled Phase 2 study of weekly oral ecnoglutide in 206 adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus at least one weight-related comorbidity such as hypertension, dyslipidemia, or cardiovascular disease [4]. Primary endpoint: mean percent change in body weight from baseline. The ClinicalTrials.gov registration lists the primary endpoint timepoint in the week 24-28 range, which is standard for Phase 2 obesity dose-finding work; this is shorter than the week 48-72 windows used in key obesity Phase 3 trials and limits direct cross-trial comparison. What makes the trial notable is the route. Oral peptide GLP-1 dosing is hard - peptides degrade in the gut, which is why Rybelsus requires a daily fasted dose with strict water and food rules, and even then real-world bioavailability (the fraction of the swallowed dose that actually reaches the bloodstream) sits around 1%, producing about half the weight loss of injectable semaglutide in head-to-head work. A once-weekly oral peptide would be a meaningful patient-experience win if bioavailability is reproducible across patients. The trial is ACTIVE_NOT_RECRUITING, so enrollment is closed. The absence of an active comparator is a real limitation. Placebo-controlled data tells you the molecule works versus nothing, but the commercially relevant question is whether it competes with semaglutide and tirzepatide on weight loss and tolerability. That answer requires a separate head-to-head Verdiva will need to fund.

This drug has a 9% chance of eventually being approved, according to our model. The starting point is the historical approval rate for Phase 2 drugs in this area - about 35% - and then the model adjusts that figure using ten facts about the trial and sponsor. The biggest drags on the estimate are the sponsor's thin approval record, weak earlier-phase results, heavier-than-usual blinding, and a randomized trial design. The remaining factors are close to average for this stage, so they don't move the number much in either direction.

The single biggest commercial risk is orforglipron, Lilly's daily oral small-molecule GLP-1RA, expected to read out key Phase 3 obesity data in late 2025 through 2026 with anticipated weight loss in the 13-15% range. Orforglipron is not a peptide - it does not face the gut-degradation problem that defines VRB-101's main technical risk, does not require fasting windows, and is straightforward to scale-manufacture. If Lilly's Phase 3 clears and orforglipron reaches the US market in 2026-2027, the 'oral GLP-1' niche that VRB-101 is being built for largely collapses before VRB-101 reaches its own Phase 3. The realistic remaining commercial pocket would be patients who fail or are intolerant to small-molecule options, or markets where Lilly's pricing leaves room - a much smaller addressable population than the headline obesity TAM. Other risks: (1) Efficacy ceiling. Tirzepatide produced 20.9% mean weight loss at week 72 in SURMOUNT-1 (15mg arm) [7]; retatrutide is tracking ~24% at week 48 in Phase 2 (Phase 3 ongoing) [8]; Sciwind's Chinese Phase 3 obesity data for the injection showed roughly 10-12% placebo-adjusted at week 48 [1] - competitive in absolute terms but not category-leading, and the oral formulation will likely underperform the injection on PK. (2) Oral peptide bioavailability variability is a known headache for this route, and weekly dosing amplifies swings - Rybelsus achieves ~1% bioavailability with strict fasting rules. (3) Timing. If Verdiva reads Phase 2 in late 2026 and runs Phase 3 through 2029, the US standard of care at launch will likely be tirzepatide and orforglipron. (4) Payer pressure. Obesity coverage in the US remains spotty, and any new GLP-1 will fight for formulary position against entrenched Lilly and Novo contracts.

Worth watching, not yet a signal. The Phase 2 readout from NCT07281937 is the trigger event, expected Q3-Q4 2026. Three data points matter: (1) placebo-adjusted weight loss at the primary timepoint (likely week 24-28) - needs to extrapolate to a credible 10-12%+ at a Phase 3 timepoint to keep pace with the Chinese injection data, and to a 15%+ trajectory to be genuinely interesting versus tirzepatide; (2) GI tolerability - the cAMP-bias differentiator claim is not strongly supported by the Sciwind Phase 3 data so far (nausea and vomiting rates are in line with the class [1][2][3]), so a noticeably cleaner Phase 2 GI profile in the oral arm would change the story; (3) oral PK reproducibility and dosing burden - does the weekly oral hold up across patients without Rybelsus-style fasting rules. The Verdiva-Sciwind structure is also worth flagging for investors: VRB-101 appears to be an ex-Greater China sublicense rather than independently developed chemistry, and Verdiva's ~$410M Series A [6] gives it the runway to reach Phase 2 readout and negotiate a deal but not to independently commercialize. The most plausible monetization path is a partnership or acquisition by a metabolic-focused player after the Phase 2 readout. If the data clear the bar and orforglipron disappoints, this becomes M&A bait at a category premium. If weight loss lands at 8-10% or orforglipron clears Phase 3 first, it joins the growing pile of also-rans in the most crowded therapeutic category in pharma.